Comparison of ABT-869 with other FLT3 and VEGFR/PDGFR inhibitors
| Cell line . | Proliferation IC50, nM . | ||||
|---|---|---|---|---|---|
| ABT-869 . | MLN-518 . | CHIR-258 . | Sunitinib . | Sorafenib . | |
| MV-4-11* | 4 | 74 | 9 | 5 | 4 |
| RS4;11† | 2100 | > 10 000 | 630 | 1700 | 3500 |
| MOLM-13* | 6 | 73 | 8 | ND | 9 |
| SUP-B15† | 5000 | ND | 200 | 4000 | > 1000 |
| Kasumi-1‡ | 16 | 300 | 77 | 22 | 20 |
| Cell line . | Proliferation IC50, nM . | ||||
|---|---|---|---|---|---|
| ABT-869 . | MLN-518 . | CHIR-258 . | Sunitinib . | Sorafenib . | |
| MV-4-11* | 4 | 74 | 9 | 5 | 4 |
| RS4;11† | 2100 | > 10 000 | 630 | 1700 | 3500 |
| MOLM-13* | 6 | 73 | 8 | ND | 9 |
| SUP-B15† | 5000 | ND | 200 | 4000 | > 1000 |
| Kasumi-1‡ | 16 | 300 | 77 | 22 | 20 |
ND indicates not determined for this cell line.
*AML cell line with FLT3-ITD.
†ALL cell line with wt-FLT3.
‡AML cell line with KIT N822K mutation.